JJ, I think he may have been advised to not tout the mono-therapy results (by FDA and/or attorneys) since the primary end point for the 26/31 weeks was safety with a view as to the average of participants data being a secondary one. The mono results were not an end point and therefore was not in the context of the study.
With the extensions, the mono end point will become a primary one, I believe.
News 
Market Data 
Discover 
